AIM IP specialist Tekcapital to sell or float all four portfolio companies 'within 2 years'. Watch the full video here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksDestiny Pharma. Share News (DEST)

Share Price Information for Destiny Pharma. (DEST)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 142.50
Bid: 140.00
Ask: 145.00
Change: 3.00 (2.15%)
Spread: 5.00 (3.57%)
Open: 139.50
High: 142.50
Low: 140.00
Yest. Close: 139.50
DEST Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

RNS Alerts are a premium feature

Login to your account

myTerminal is a premium feature

Login to your account

Don't have an account? Click here to register.

IN BRIEF: Destiny Pharma Notes XF-73 Study Recruitment On Track

Thu, 17th Sep 2020 19:09

Destiny Pharma PLC - clinical stage biotechnology company - Notes recruitment for Phase 2b clinical study of lead asset XF-73 on track to complete by year-end and report results in early 2021. The phase 2b clinical study is recruiting patients undergoing open heart surgery in US and Europe. Barring any further impact from Covid-19 the study is on plan to complete recruitment by the end of 2020 and report results in the first quarter of 2021.

Chief Executive Neil Clark said: "We are very pleased to report a significant increase in the screening and recruitment of patients in our lead clinical study testing XF-73 as a novel product preventing the incidence of post-surgical infections such as MRSA. In the past few months we have agreed a protocol amendment with the FDA and also reported excellent interim safety data and are looking forward to completing recruitment and reporting the results."

Current stock price: 63.00 pence

Year-to-date change: up 43%

By Paul McGowan; paulmcgowan@alliancenews.com

Copyright 2020 Alliance News Limited. All Rights Reserved.

More News

TRADING UPDATES: Quixant swings to 2020 loss but recommends dividend

TRADING UPDATES: Quixant swings to 2020 loss but recommends dividend

14 Apr 21 12:04

UK earnings, trading statements calendar - next 7 days

UK earnings, trading statements calendar - next 7 days

7 Apr 21 15:58

AIM WINNERS & LOSERS: Destiny Pharma jumps on positive nasal gel study

AIM WINNERS & LOSERS: Destiny Pharma jumps on positive nasal gel study

29 Mar 21 09:59

Destiny Pharma jumps as infection-fighting nasal gel shows promise

Destiny Pharma jumps as infection-fighting nasal gel shows promise

29 Mar 21 09:02

TRADING UPDATES: Arix backs buyback; 88 Energy notes share price surge

TRADING UPDATES: Arix backs buyback; 88 Energy notes share price surge

15 Mar 21 21:44

IN BRIEF: Destiny Pharma CSO joins UK Covid-19 research taskforce

IN BRIEF: Destiny Pharma CSO joins UK Covid-19 research taskforce

10 Mar 21 20:22

IN BRIEF: Destiny Pharma Secures Brazilian Patent For XF-73 Nasal Gel

IN BRIEF: Destiny Pharma Secures Brazilian Patent For XF-73 Nasal Gel

3 Feb 21 11:09

IN BRIEF: Destiny Pharma Adds Mark Wilcox To Scientific Advisory Board

IN BRIEF: Destiny Pharma Adds Mark Wilcox To Scientific Advisory Board

2 Feb 21 14:34

UK EXECUTIVE CHANGE SUMMARY: Martin Gilbert Joins River & Mercantile

UK EXECUTIVE CHANGE SUMMARY: Martin Gilbert Joins River & Mercantile

6 Jan 21 14:27

IN BRIEF: Destiny Pharma Completes Recruitment For XF-73 Gel Trial

IN BRIEF: Destiny Pharma Completes Recruitment For XF-73 Gel Trial

5 Jan 21 21:15

Destiny Pharma meets recruitment deadline for XF-73 trial

(Sharecast News) - Clinical-stage biotechnology company Destiny Pharma announced on Tuesday that its XF-73 phase 2b clinical trial was fully recruited by 31 December, meeting the target timeline set for the programme.

5 Jan 21 11:21

UK TRADING UPDATE SUMMARY: Lekoil Fires Back At Shareholder Metallon

UK TRADING UPDATE SUMMARY: Lekoil Fires Back At Shareholder Metallon

22 Dec 20 18:06

UK TRADING UPDATE SUMMARY: SourceBio Tips Jump In Virus Testing Demand

UK TRADING UPDATE SUMMARY: SourceBio Tips Jump In Virus Testing Demand

25 Nov 20 18:00

Destiny Pharma Set For GBP11.5 Million Raise To Buy NTCD-M3

Destiny Pharma Set For GBP11.5 Million Raise To Buy NTCD-M3

9 Nov 20 17:15

IN BRIEF: Destiny Pharma Set To Complete Study Recruitment By 2020 End

IN BRIEF: Destiny Pharma Set To Complete Study Recruitment By 2020 End

12 Oct 20 14:42

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.